Amgen files Xgeva in US for prostate cancer prevention
This article was originally published in Scrip
Executive Summary
Amgen has submitted a supplemental BLA to the US FDA seeking to expand the indication for denosumab, known as Xgeva, to treat men with castrate-resistant prostate cancer (CRPC) to reduce the risk of developing bone metastases, based on the results of a single Phase III study ('147).